“Our team has made nothing short of transformational advancements throughout 2024. Fundamentally, the Company has never been stronger, and we believe we are poised to unlock value for all stakeholders in the near term,” commented John Climaco, Chief Executive Officer of CNS Pharmaceuticals (CNSP). “We have a strong cash position, expanded our pipeline in complete alignment with our mission and importantly, believe we are closer than ever to potentially bringing Berubicin, our targeted chemotherapy drug candidate, to market as a meaningful treatment option to GBM patients and practitioners.”
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio